Characteristics | CTXNS-En (n = 37) | CTXS-En (n = 74) | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|---|
OR (95% CI) | P-value | OR (95% CI) | P-value | |||
Age | 66 (19–93) | 67 (19–90) |  | 0.98 |  |  |
Male | 24 (65%) | 41 (55%) | Â | 0.34 | Â | Â |
Nosocomial or healthcare-associated bacteremia | 34 (92%) | 59 (80%) | 2.88 (0.73–16.49) | 0.17 |  |  |
Previous isolation of MDR bacteria | 15 (41%) | 9 (12%) | 4.92 (1.71–14.51) | <0.01 |  |  |
Previous isolation of CTXNS-En | 17 (46%) | 6 (8%) | 9.63 (3.04–33.20) | <0.01 | 12.32 (3.69–41.12) | <0.01 |
Previous isolation of fluoroquinolone-resistant Enterobacteriaceae | 11 (30%) | 7 (9%) | 4.05 (1.26–13.58) | 0.01 |  |  |
Previous ICU admission within 30 days | 9 (24%) | 11 (15%) | 1.84 (0.60–5.50) | 0.29 |  |  |
Previous antibiotic use within 30 daysa | ||||||
 Any antibiotics | 28 (76%) | 38 (51%) | 2.95 (1.14–8.04) | 0.02 |  |  |
 Penicillins | 2 (5%) | 2 (3%) | 2.06 (0.14–29.27) | 0.60 |  |  |
 Third-generation cephalosporins | 8 (22%) | 7 (9%) | 2.64 (0.75–9.36) | 0.09 |  |  |
 Other cephems | 15 (41%) | 14 (19%) | 2.92 (1.11–7.69) | 0.02 |  |  |
 β-lactam/β-lactamase inhibitors | 6 (16%) | 3 (4%) | 4.58 (0.90–29.66) | 0.06 |  |  |
 Carbapenems | 6 (16%) | 5 (7%) | 2.67 (0.62–11.85) | 0.18 |  |  |
 Fluoroquinolones | 6 (16%) | 7 (9%) | 1.85 (0.47–7.01) | 0.35 |  |  |
 Aminoglycosides | 0 (0%) | 1 (1%) | 0 | 1.00 |  |  |
 Trimethoprim/sulfamethoxazole | 8 (22%) | 14 (19%) | 1.18 (0.38–3.43) | 0.80 |  |  |
 Glycopeptides | 7 (19%) | 6 (8%) | 2.61 (0.68–10.17) | 0.12 |  |  |
Duration of previous antibiotic use | 11 (0–30) | 7 (0–30) |  | 0.02 |  |  |
Charlson index | 4 (0–9) | 3 (0–14) |  | 0.21 |  |  |
Hematological malignancy | 7 (19%) | 7 (9%) | 2.23 (0.60–8.14) | 0.22 |  |  |
Solid malignancy | 11 (30%) | 30 (41%) | 0.62 (0.24–1.55) | 0.30 |  |  |
Transplantation | 10 (27%) | 6 (8%) | 4.20 (1.22–15.31) | 0.01 |  |  |
Hemodialysis | 4 (11%) | 5 (7%) | 1.67 (0.31–8.30) | 0.48 |  |  |
Diabetes | 9 (24%) | 19 (26%) | 0.93 (0.33–2.51) | 1.00 |  |  |
Cardiac disease | 18 (49%) | 16 (22%) | 3.43 (1.35–8.75) | <0.01 | 5.00 (1.64–15.28) | <0.01 |
Chronic lung disease | 8 (22%) | 12 (16%) | 1.43 (0.45–4.27) | 0.60 |  |  |
Liver disease | 10 (27%) | 17 (23%) | 1.24 (0.44–3.33) | 0.65 |  |  |
Pancreatobilliary disease | 4 (11%) | 20 (27%) | 0.33 (0.08–1.11) | 0.05 |  |  |
Chronic kidney disease | 13 (35%) | 27 (36%) | 0.94 (0.38–2.31) | 1.00 |  |  |
Connective tissue disease | 4 (11%) | 8 (11%) | 1.00 (0.21–4.06) | 1.00 |  |  |
Intravascular catheter | 31 (84%) | 40 (54%) | 4.39 (1.54–14.26) | <0.01 | 5.33 (1.46–19.49) | 0.01 |
Urinary catheter | 16 (43%) | 19 (26%) | 2.21 (0.88–5.50) | 0.08 |  |  |
Mechanical ventilation | 6 (16%) | 4 (5%) | 3.39 (0.73–17.31) | 0.08 |  |  |
Other artificial devices | 19 (51%) | 22 (30%) | 2.49 (1.02–6.10) | 0.04 |  |  |
Use of immunosuppressive therapy within 30 days | 20 (54%) | 40 (54%) | 1.00 (0.42–2.39) | 1.00 |  |  |
Neutropenia | 5 (14%) | 12 (16%) | 0.807 (0.20–2.74) | 0.79 |  |  |
Previous surgery within 30 daysb | 12 (32%) | 6 (8%) | 5.44 (1.65–19.34) | <0.01 | 4.37 (1.17–16.41) | 0.03 |
Invasive procedure within 30 days | 17 (46%) | 18 (24%) | 2.64 (1.05–6.63) | <0.03 |  |  |
Source of infection | ||||||
 Urinary tract infection | 8 (22%) | 16 (22%) | 1.00 (0.33–2.83) | 1.00 |  |  |
 Intraabdominal infection | 7 (19%) | 18 (24%) | 0.73 (0.23–2.09) | 0.63 |  |  |
 Pneumonia | 2 (5%) | 2 (3%) | 2.06 (0.14–29.27) | 0.60 |  |  |
 Primary bacteremia | 14 (38%) | 26 (35%) | 1.12 (0.45–2.74) | 0.84 |  |  |
 Other infection | 6 (16%) | 12 (16%) | 1.00 (0.28–3.22) | 1.00 |  |  |
SOFA score | 3 (0–10) | 3 (0–21) |  | 0.34 |  |  |